Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 4
Opinion
Video
Unresponsive NMIBC: Gene Therapies
Author(s):
Key Takeaways
- Targeted gene therapy personalizes treatment for BCG-unresponsive NMIBC, improving efficacy and minimizing systemic side effects by focusing on specific genetic mutations.
- Gene therapies that do not require specialized equipment, such as biosafety hoods, simplify administration and reduce logistical burdens on clinics.
Katie S. Murray, DO, discusses how the introduction of targeted gene therapies has shifted the approach to managing BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), offering more personalized treatment options, and explains how the ease of administration—without the need for specialized equipment like biosafety hoods—reduces logistical burdens on clinics.
Video Player is loading.
- How has the introduction of targeted gene therapy changed the way you approach managing BCG-unresponsive NMIBC?
- Newer gene therapies may not require specialized equipment, such as biosafety hoods, for administration. How does this ease the burden on clinics?
Related Videos
Future Directions of BCG-Unresponsive NMIBC Management
Adoption of New Treatments for BCG-Unresponsive NMIBC
Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations
The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment
Navigating BCG-Unresponsive NMIBC and Emerging Therapies
Enhancing Access to BCG-Unresponsive NMIBC Treatments
Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC
Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC
Discussing Treatment Options for BCG-Unresponsive NMIBC
Related Content
